News|Articles|July 15, 2026
Bundibugyo Ebola Explained: Why Existing Vaccines Don't Work and What Comes Next
The latest Ebola outbreak is raising new challenges for global public health. Existing Ebola vaccines were designed for a different viral strain, leaving health care workers and communities to rely on supportive care while researchers test promising new treatments and vaccine candidates. Learn what this means for infection prevention professionals.
Advertisement
A particular silence settles over a treatment team when the staff learns the strain of Ebola, they are treating has no approved vaccine or treatment. This Ebola outbreak announced itself in early May. A hospital in the northeastern Democratic Republic of the Congo (DRC) identified a cluster of severe illness among its own staff. 1 It wasn’t until the middle of May that the specific strain was identified as the Bundibugyo virus, the cause of Bundibugyo virus disease (BVD).
There is no licensed vaccine approved to prevent it. There is no licensed therapeutic approved to treat it.1 When the World Health Organization (WHO) convened its Research and Development Blueprint technical advisory groups at the end of May, the task was to review every candidate therapeutic and vaccine that might work. The experts came back with a short list of candidates worth evaluating in clinical field trials.2
This isn’t a solution for today, but a tool for tomorrow. Today, the current situation is outlined below (Figure 1).
For each of these patients, the clinicians standing at those bedsides were only able to provide supportive care.
Why Don’t Our Current Ebola Treatments Work?
There are Ebola countermeasures and licensed vaccines, including monoclonal antibody therapeutics. The challenge is that they were designed to target a different strain of Ebola, the Zaire ebolavirus.1
All is not lost; the WHO advisory group identified 3 promising therapies: a monoclonal antibody, MBP134; a single-antibody, maftivimab; and an antiviral, remdesivir.
Previously, every monoclonal antibody and antibody cocktail that reached clinical development was highly specific to a single member of the Ebolavirus genus, rendering them ineffective against the Bundibugyo and Sudan viruses.3,4 In contrast, the antibodies comprising MBP134 were selected specifically for their pan-ebolavirus reactivity. This 2-antibody cocktail targets 2 different, non-overlapping sites on the ebolavirus surface glycoprotein (GP).4
Mechanistically, they successfully neutralize the virus at multiple stages, acting against both the original GP outside the cell and the altered version found inside host cells. Additionally, the antibodies bind specifically to the actual virus, avoiding interaction with the circulating decoy proteins (secreted GP) that heavily flood a patient's bloodstream during infection.4
Current vaccines fail for a related reason. Per the CDC, data from animal studies indicate that the Ebola vaccine licensed in the US is not expected to confer cross-protection against the Bundibugyo virus or other orthoebolaviruses.5 Additionally, a WHO review concluded that available data are insufficient to reliably estimate effectiveness against BVD.5,6 This evidence relies on small nonhuman primate models and inconsistent laboratory data. Consequently, official guidance advises against using the licensed vaccine during BVD outbreaks except within controlled research settings.6
There are Ebola therapeutic options, just none that are confirmed as effective and licensed for the current BVD outbreak, yet.
What About an Ebola Vaccine?
WHO recommended a single-dose recombinant vesicular stomatitis virus (rVSV) Bundibugyo vaccine, under development, as the most promising. It is estimated that it will take 7 to 9 months before it is ready for assessment in a clinical trial.2 A chimpanzee adenovirus-vectored candidate, ChAdOx1 Bundibugyo could potentially be available within 2 to 3 months for efficacy assessment. Though additional animal data are still required.2
The advisory group noted that a single-dose approach might suit contacts, while a 2-dose strategy could be considered for high-risk unexposed populations: frontline responders and health care workers.2 To expedite this process, funds have been allocated to accelerate preclinical work and phase 1 trials across the Bundibugyo candidates.7
In 2013, investigators published nonhuman primate data showing that VSV-based vaccines protect against lethal Bundibugyo virus challenge.8 Bundibugyo virus was identified in 2007, in an outbreak in western Uganda that produced 131 confirmed cases. It appeared again in the DRC in 2012, with 62 confirmed cases.1 Both outbreaks were small. Neither generated the kind of commercial demand that moves research to product development; need and money simply weren’t there.
What Is Being Tested in Patients?
On July 2, 2026, the Platform Adaptive Randomized Trial for New and Repurposed Filovirus TreatmentS (PARTNERS) opened enrollment in the DRC.9 The design is worth understanding, because it answers a question our colleagues may ask. Patients with confirmed BVD are randomly assigned to 4 groups.10
- Group 1 receives standard care alone (eg, aggressive fluid and electrolyte replacement, symptom management, and antibiotics or antimalarials where secondary infection is suspected).
- Groups 2 and 3 receive standard care plus MBP134 or standard care plus remdesivir.
- Group 4 receives both drugs.
The primary end point is mortality at 28 days. The trial is expected to run for 6 months and enroll between 700 and 1,000 participants.10 No one is randomized to nothing. Everyone gets supportive care; that distinction matters. Of the 3, only MBP134 and remdesivir entered the PARTNERS platform at launch; maftivimab was prioritized but is not yet among the trial arms.2,9
MBP134 is a pair of broadly neutralizing human antibodies isolated from a survivor of the 2014 to 2016 West African epidemic. It acts as a pan-ebolavirus tool, designed to work against multiple Ebola species at once, including Bundibugyo.4 In preclinical work, a single dose protected nonhuman primates against lethal challenge with Zaire, Sudan, and Bundibugyo ebolavirus.3 The antibody has human safety data from a small phase 1 study.11
There is a second therapy. In June, more than 2,000 vials of remdesivir were donated to Uganda for use under compassionate use and Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) frameworks.12 MEURI is WHO's own mechanism: it permits investigational products outside a randomized trial during an emergency, provided use occurs under an approved protocol with prospective data collection.
For the first time in 19 years, since this virus was named, a patient with BVD has been enrolled in a study of a treatment for BVD. The PARTNERS trial opened enrollment at the beginning of July 2026.9
Can We Protect the Exposed Before They Get Sick?
For postexposure prophylaxis (PEP) among contacts of confirmed and probable cases, WHO's advisory group prioritized obeldesivir, an oral antiviral administered as tablets.2 Obeldesivir is a prodrug that shares an active metabolite with remdesivir. The clinical difference is not the pharmacology; it is logistics. One is an intravenous infusion, and the other is a pill. From a public health management perspective, the logistical and clinical value of this distinction is substantial.
The advisory group attached a condition to its recommendation, and it is one we recognize immediately. This approach depends on effective contact tracing, which remains operationally challenging in some of the affected areas of the DRC.2 As of July 8, 78.6% of identified case contacts across Ituri and North Kivu were under follow-up, down from 82.7% a week earlier.13,14 This declining metric amidst an expanding outbreak illustrates the core operational challenge: contact generation is outstripping tracing capacity. Ultimately, this deficit imposes a strict boundary on the success of any prophylaxis campaign. PEP interventions cannot be administered to unidentified contacts.
WHO has reported that a trial of obeldesivir for PEP has been prepared and its drug supply is in country, but as of this writing it had not been confirmed as open to enrollment.15
What Does This Change in the Outbreak Right Now?
Very little. Not yet.
Investigational therapeutics do not directly lower the reproduction number, disrupt transmission chains in insecure zones, or enforce infection control protocols. Instead, their clinical utility depends entirely on existing public health infrastructure; untraced contacts cannot receive prophylaxis, and delayed presentations compromise therapeutic efficacy. Rather than replacing active case finding, contact tracing, and isolation, these countermeasures increase their value by providing foundational epidemiological efforts with a viable clinical destination.
Consequently, regional preparedness now requires extensive enhancements to the nonlaboratory framework, including cold chain optimization, site identification, clinical practice training, and diagnostic expansion. Clinical trial readiness must therefore be integrated alongside isolation capacity and personal protective equipment protocols as a core domain of institutional facility planning.16
While research proceeds, the immediate priority remains interrupting transmission. This relies on the standard public health measures we follow for every outbreak. These foundational interventions include robust surveillance, rapid diagnostic testing, rigorous contact tracing, isolation, quality patient care, strict infection control, community engagement, and safe burials.2,17 This infrastructure is essential, as CDC modeling confirms that the interval between outbreak onset and detection directly dictates epidemic scale and duration.17
Why a Vaccine Still Matters
As of July 9, a reported 112 health care workers had been infected across the DRC since the outbreak began, with 35 counted as fatalities.18 The people treating the patients become patients themselves.
To be clear, the value of a licensed Bundibugyo vaccine was never that it could end this outbreak. Its value is prevention: the health care workers who would never have been exposed, the contacts who would never have fallen ill. That is where we count the wins as public health professionals. Not in the patients we treat, but in the cases that never happen. The tools are finally coming. The question is whether they arrive before the next caregiver becomes a patient.
References
1. Sullivan NJ. Bundibugyo virus disease in 2026—clinical and public health responses. N Engl J Med. Published online June 24, 2026. Accessed July 10, 2026. doi:10.1056/NEJMra2607216
2. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus. World Health Organization. May 28, 2026. Accessed July 10, 2026.
3. Bornholdt ZA, Herbert AS, Mire CE, et al. A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe. 2019;25(1):49-58.e5. doi:10.1016/j.chom.2018.12.005
4. Wec AZ, Bornholdt ZA, He S, et al. Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection. Cell Host Microbe. 2019;25(1):39-48.e5. doi:10.1016/j.chom.2018.12.004
5. Ebola disease outbreak in the Democratic Republic of the Congo and Uganda. CDC. Health Alert Network Health Advisory CDCHAN-00530. May 19, 2026. Accessed July 10, 2026.
6. WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks. World Health Organization. May 28, 2026. Accessed July 10, 2026.
7. CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates. Coalition for Epidemic Preparedness Innovations. June 1, 2026. Accessed July 10, 2026.
8. Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013;7(12):e2600. doi:10.1371/journal.pntd.0002600
9. Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease. World Health Organization. July 2, 2026. Accessed July 10, 2026.
10. Start of the PARTNERS clinical trial. Press release. Institute of Tropical Medicine. July 2026. Accessed July 10, 2026.
11. Liu G, He S, Chan M, et al. A pan-ebolavirus monoclonal antibody cocktail provides protection against Ebola and Sudan viruses. J Infect Dis. 2023;228(suppl 7):S691-S700. doi:10.1093/infdis/jiad205
12. Gilead mobilizes rapid donation of remdesivir to support Ebola response. Gilead Sciences. June 11, 2026. Accessed July 10, 2026.
13. Ebola disease outbreak in the Democratic Republic of the Congo and Uganda. European Centre for Disease Prevention and Control. Updated July 10, 2026. Accessed July 12, 2026.
14. Ebola disease outbreak in the Democratic Republic of the Congo and Uganda. European Centre for Disease Prevention and Control. Updated July 2, 2026. Accessed July 12, 2026.
15. Kupferschmidt K. First-ever treatment trial for Ebola Bundibugyo kicks off in the Congo. Science. Published July 2, 2026. Accessed July 12, 2026. doi:10.1126/science.zyvmn4t
16. Ongoing outbreak in the Democratic Republic of the Congo. World Health Organization Regional Office for Africa. Accessed July 10, 2026.
17. Mooring EQ, Koval WT, Routledge I, et al. Modeled scenario projections for the Ebola disease outbreak caused by Bundibugyo virus, 2026. MMWR Morb Mortal Wkly Rep. 2026;75(22):285-289. doi:10.15585/mmwr.mm7522e1. Accessed July 10, 2026.
18. Africa CDC calls for stronger protection of responders. Africa Centres for Disease Control and Prevention. July 9, 2026. Accessed July 10, 2026.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement